# biblio
1. Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: A review. JAMA - Journal of the American Medical Association 311, 1670–1683 (2014).

2. Björklund, A., Dunnett, S. B., Stenevi, U., Lewis, M. E. & Iversen, S. D. Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 199, 307–333 (1980).

3. Freund, T. F. et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: A tyrosine hydroxylase immunocytochemical study. Journal of Neuroscience 5, 603–616 (1985).

4. Bolam, J., Freund, T., Björklund, A., Dunet, S. & Smith, A. Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum. Exp Brain Res 68, 131–146 (1987).

5. Strecker, R. E. et al. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 22, 169–178 (1987).

6. Dunnett, S. B., Björklund, A., Schmidt, R. H., Stenevi, U. & Iversen, S. D. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral implants of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. 522, 29–38 (1983).

7. Barker, R. A. et al. Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nat Med 25, (2019).

8. Arenas, E., Denham, M. & Villaescusa, J. C. How to make a midbrain dopaminergic neuron. Development (Cambridge) 142, 1918–1936 (2015).
   
9. Doi, D. et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2, 337–350 (2014).

10. Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature 548, 592–596 (2017).

11. Samata, B. et al. Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. Nat Commun 7, 1–11 (2016).

12. Lehnen, D. et al. IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells. Stem Cell Reports 9, 1207–1220 (2017).

13. Gennet, N., Tamburini, C., Nan, X. & Li, M. FolR1: A novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons. Sci Rep 6, 1–10 (2016).

14. Bye, C. R., Jönsson, M. E., Björklund, A., Parish, C. L. & Thompson, L. H. Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors. Proc Natl Acad Sci U S A 112, E1946–E1955 (2015).

15. Paik, E. J., O’Neil, A. L., Ng, S. Y., Sun, C. & Rubin, L. L. Using intracellular markers to identify a novel set of surface markers for live cell purification from a heterogeneous hIPSC culture. Sci Rep 8, 1–8 (2018).

16. Fathi, A. et al. Discovery of novel cell surface markers for purification of embryonic dopamine progenitors for transplantation in Parkinson’s disease animal models. Molecular and Cellular Proteomics 17, 1670–1684 (2018).

17. Sundberg, M. et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31, 1548–1562 (2013).

18. Yoo, J. E. et al. Trophoblast glycoprotein is a marker for efficient sorting of ventral mesencephalic dopaminergic precursors derived from human pluripotent stem cells. NPJ Parkinsons Dis 7, (2021).
